EUVIMEDEUVIMED entdecken
Fallbericht

Characteristics of virus and antibody response in an immunocompromised patient with persistent SARS-CoV-2 infection

Shunsuke Yazawa, Kei Fukuyama, Rie Kawakami, Masae Itamochi, Daiki Higashi, Noriaki Tsuji, Masahiko Nakamura, Kazunori Oishi, Hiroyasu Kaya, Hideki Tani

Journal of Infection and Chemotherapy · 2025

DOI: 10.1016/j.jiac.2024.08.024 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Infection and Chemotherapy, 2025. Verfasst von Shunsuke Yazawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Virology, Toyama Institute of Health, Toyama, Japan. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Antibodies, Viral, COVID-19, Immunocompromised Host. Die Arbeit nennt 11 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We have previously reported a clinical case in which a hospitalized patient with a history of hematopoietic stem cell transplantation for acute myeloid leukemia was persistently infected with SARS-CoV-2. This study investigated the neutralizing activity of patient sera against cultured viruses isolated at each time point. We also continued to decipher and analyze the whole-genome sequence of the virus. The results showed that the neutralizing activity against the cultured virus at each time point was higher in the sera collected in the late stage of infection. However, the cultured virus collected in the late stage of infection was less likely to be neutralized not only by the sera collected in the early stage of infection but also by the sera collected in the late stage. Moreover, the virus mutated in a manner that allowed it to escape neutralizing antibodies in a host vulnerable to prolonged infection, such as immunocompromised patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingAntibodies, ViralCOVID-19Immunocompromised HostSARS-CoV-2HumansGenome, ViralHematopoietic Stem Cell TransplantationLeukemia, Myeloid, Acute

Stichwörter der Autor:innen

Growth efficiencyNeutralizing antibodyPersistent infectionSARS-CoV-2Viral isolation

Substanzen

Antibodies, NeutralizingAntibodies, Viral

Autor:innen und Institutionen

  • Department of Virology, Toyama Institute of Health, Toyama, Japan.
  • Toyama Prefectural Central Hospital, Toyama, Japan.
  • Toyama Institute of Health, Toyama, Japan.
  • Department of Virology, Toyama Institute of Health, Toyama, Japan. Electronic address: toyamaeiken3@juno.ocn.ne.jp.

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Yazawa, S., Fukuyama, K., Kawakami, R., Itamochi, M., Higashi, D., Tsuji, N., Nakamura, M., Oishi, K., Kaya, H., & Tani, H. (2025). Characteristics of virus and antibody response in an immunocompromised patient with persistent SARS-CoV-2 infection. Journal of Infection and Chemotherapy. https://doi.org/10.1016/j.jiac.2024.08.024

Vancouver

Yazawa S, Fukuyama K, Kawakami R, Itamochi M, Higashi D, Tsuji N, et al. Characteristics of virus and antibody response in an immunocompromised patient with persistent SARS-CoV-2 infection. Journal of Infection and Chemotherapy. 2025. doi:10.1016/j.jiac.2024.08.024

BibTeX
@article{Yazawa2025,
  author = {Yazawa, Shunsuke and Fukuyama, Kei and Kawakami, Rie and Itamochi, Masae and Higashi, Daiki and Tsuji, Noriaki and Nakamura, Masahiko and Oishi, Kazunori and Kaya, Hiroyasu and Tani, Hideki},
  title = {Characteristics of virus and antibody response in an immunocompromised patient with persistent SARS-CoV-2 infection},
  journal = {Journal of Infection and Chemotherapy},
  year = {2025},
  doi = {10.1016/j.jiac.2024.08.024}
}
Kostenlos starten →